Launches Archives - Pharmaceutical Business review

Processandproduction Pharmaceutical Business Review. FDA grants priority review to Enasidenib for IDH2-Mutant AML ...

Read Processandproduction.pharmaceutical-business-review.com news digest here: view the latest Processandproduction Pharmaceutical Business Review articles and content updates right away or get to their most visited pages. Processandproduction.pharmaceutical-business-review.com is not yet rated by Alexa and its traffic estimate is unavailable. It seems that Processandproduction Pharmaceutical Business Review content is notably popular in USA. We haven’t detected security issues or inappropriate content on Processandproduction.pharmaceutical-business-review.com and thus you can safely use it. Processandproduction.pharmaceutical-business-review.com is hosted with Amazon Technologies Inc. (United States) and its basic language is English.

  • Content verdict: Safe
  • Website availability: Live
  • English language flagLanguage: English
  • Last check:
  • N/A

    Visitors daily
  • N/A

    Pageviews daily
  • 5

    Google PR
  • N/A

    Alexa rank

Processandproduction.pharmaceutical-business-review.com news digest

  • 3 years

    TFF Pharmaceuticals, Felix Biotechnology sign LOI for collaboration, development...

    Under this proposed CDLA agreement, Felix Biotechnology would obtain a worldwide license to TFF Pharmaceuticals’ Thin Film Freezing technology to develop and manufacture dry powder formulations of a novel, bacteriophage-based biotherapeutics for inhalation...

  • 3 years

    Merck to buy biopharmaceutical firm VelosBio for $2.75bn

    Based in San Diego, VelosBio is involved in the development of first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1).
    VLS-101, the company’s investigational antibody-drug conjugate (ADC) targeting ROR1, is currently being assessed in a phase I and a phase 2 clinical study to treat patients with haematologic malignancies and solid tumours....

  • 3 years

    NanOlogy enrols first patient in phase 2 trial of NanoPac for intratumoral treat...

    The single arm trial is evaluating up to 3 monthly injections of the investigational drug in patients scheduled for prostatectomy approximately 90 days after the first injection.
    Patients will be followed for safety and tumor response. Immune effects will be evaluated via multiplex immunohistochemistry and flow cytometry....

  • 3 years

    XNK Therapeutics receives US orphan drug status for NK cell-based immunotherapy ...

    Receiving ODD status from the FDA for the treatment of multiple myeloma is a critical next step for the development of XNK’s leading investigational drug candidate. XNK has already received ODD status in the EU.
    “Obtaining an ODD by the FDA is a significant milestone for XNK and our goal of taking the present drug candidate to the next level,” said Johan Liwing, CEO of XNK Therapeutics. “This is the starting point for us to expand clinical development into the...

Domain history

Web host: Amazon Technologies Inc.
Registrar: Register SPA
Registrant: REDACTED FOR PRIVACY (New Statesman Media Group Limited)
Updated: April 03, 2024
Expires: April 14, 2025
Created: April 14, 2003

Whois record

Safety scores

Trustworthiness

Good

Child safety

N/A